Charter Oak Capital Management LLC Reduces Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Charter Oak Capital Management LLC decreased its stake in Johnson & Johnson (NYSE:JNJ) by 1.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 11,115 shares of the company’s stock after selling 194 shares during the quarter. Charter Oak Capital Management LLC’s holdings in Johnson & Johnson were worth $1,742,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of JNJ. Hibernia Wealth Partners LLC purchased a new position in Johnson & Johnson during the 3rd quarter valued at $27,000. FNY Investment Advisers LLC purchased a new position in Johnson & Johnson during the 3rd quarter valued at $37,000. Keener Financial Planning LLC purchased a new position in Johnson & Johnson during the 4th quarter valued at $40,000. Tower View Wealth Management LLC boosted its holdings in Johnson & Johnson by 183.3% during the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock valued at $40,000 after acquiring an additional 165 shares during the period. Finally, Creative Capital Management Investments LLC boosted its holdings in Johnson & Johnson by 43.0% during the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock valued at $45,000 after acquiring an additional 86 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.0 %

Shares of JNJ stock opened at $147.49 on Tuesday. Johnson & Johnson has a 1-year low of $144.95 and a 1-year high of $175.97. The stock’s fifty day moving average price is $157.07 and its 200 day moving average price is $155.90. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91. The company has a market cap of $355.42 billion, a price-to-earnings ratio of 10.68, a price-to-earnings-growth ratio of 2.48 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, topping the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The firm had revenue of $21.40 billion for the quarter, compared to the consensus estimate of $21.02 billion. During the same period in the previous year, the business earned $2.35 EPS. The firm’s revenue for the quarter was down 9.7% on a year-over-year basis. On average, research analysts expect that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.

Analysts Set New Price Targets

JNJ has been the subject of a number of research analyst reports. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Morgan Stanley decreased their target price on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 24th. Raymond James lifted their target price on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Monday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 28th. Seven equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $177.31.

Insider Buying and Selling

In related news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.